A Randomized, Open-label, Multiple Dosing, Cross-over Phase 1 Clinical Trial to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 After Oral Administration in Healthy Caucasian Subjects
Latest Information Update: 21 May 2022
At a glance
- Drugs IN-C005 (Primary) ; Tegoprazan (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors HK inno.N
Most Recent Events
- 10 May 2022 Status changed from not yet recruiting to completed.
- 20 Aug 2021 New trial record